Drug Trial Radar · NCT07222488
A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
45
Planned (sponsor's estimate)
Start
Dec 9, 2025
Primary completion
Jul 30, 2027
Study completion Feb 28, 2029
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Oct 30, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for new ways to treat high-risk non-muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the inside of the bladder and has not spread to the bladder muscle or outside of the bladder. In standard treatment for HR NMIBC, doctors first remove the tumor with a procedure called transurethral resection of the bladder tumor (TURBT). Researchers want to learn if using MK-3120, the study medicine, can treat HR NMIBC after TURBT. The goal of this study is to learn about the safety of MK-3120 and if people tolerate it.
Conditions
- Bladder Cancer
- Urinary Bladder Neoplasms
Interventions
MK-3120Biological
Intravesical administration at one of three doses per protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Experience a Dose-limiting Toxicity (DLT)Time frame: Up to approximately 5 weeks
- Number of Participants Who Experience One or More Adverse Events (AEs)Time frame: Up to approximately 24 months
- Number of Participants Who Discontinue Study Treatment Due to AEsTime frame: Up to approximately 12 months
Locations
17 sites in 12 countries. Site status is shown where the registry gives one.
Michael G Oefelein Clinical Trials ( Site 0005)
Bakersfield, California · Completed
Rutgers Cancer Institute of New Jersey ( Site 0007)
New Brunswick, New Jersey · Recruiting
Carolina Urologic Research Center ( Site 0006)
Myrtle Beach, South Carolina · Recruiting
Urology Austin, PLLC ( Site 0008)
Austin, Texas · Completed
Medizinische Universität Wien ( Site 0021)
Vienna, State of Vienna, Austria · Completed
UZ Gent ( Site 0031)
Ghent, Oost-Vlaanderen, Belgium · Recruiting
CHU de Quebec - Hopital de l'Enfant-Jesus ( Site 0011)
Québec, Quebec, Canada · Recruiting
Gustave Roussy ( Site 0041)
Villejuif, Val-de-Marne, France · Recruiting
European Interbalkan Medical Center ( Site 0051)
Thessaloniki, Greece · Active not recruiting
Rabin Medical Center ( Site 0062)
Petah Tikva, Israel · Recruiting
Centro Ricerche Cliniche di Verona ( Site 0072)
Verona, Veneto, Italy · Recruiting
Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI AVL) ( Site 0081)
Amsterdam, North Holland, Netherlands · Active not recruiting
Akershus Universitetssykehus ( Site 0091)
Lorenskog, Akershus, Norway · Recruiting
Hospital Universitario Virgen de la Victoria ( Site 0111)
Málaga, Andalusia, Spain · Recruiting
Hospital Universitario 12 de Octubre ( Site 0112)
Madrid, Madrid, Comunidad de, Spain · Recruiting
Ankara University Health Practice and Research Hospitals ( Site 0132)
Ankara, Turkey (Türkiye) · Recruiting
Koc Universitesi Hastanesi ( Site 0133)
Istanbul, Turkey (Türkiye) · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.